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Conclusions. Social rehabilitation of patients with epilepsy should be based on the social 
aspects and characteristics of these patients. So we could not talk about an effective 
rehabilitation as long as we did not know the level of education, the character of the work 
performed, the composition of the family and the personal characteristics of each individual 
patient. Now this information can be compared with the general population and used by 
specialists in the field.   
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Introduction. Depression is a public health issue worldwide, including in European countries. 
Over 350 million people worldwide suffer from depression. Stigmatization of people with 
depression is an important barrier to addressing a health care specialist and respecting 
treatment. More than 50% of people with depression have never visited a mental health 
specialist to receive professional help. 
Aim of the study. To study the social and demographic characteristics of stigmatization 
towards people with depression in students from Moldova. 
Materials and methods. In a cross-sectional study, we evaluated 414 medical students. The 
data were collected on the basis of a self-reported anonymous questionnaire, through which 
beyond the stigmatization of people with depression, the individual and family characteristics 
of the participants were evaluated. Stigmatization was assessed using the Depression 
Stigmatization Assessment Scale (DSS), developed by Kathleen Griffiths. 
Results. The level of average stigmatization (standard deviation) measured by the 
Stigmatization Evaluation Scale for People with Depression (DSS) showed lower values for 
personal stigmatization (18.83 (4.88) compared to perceived stigmatization [26.21 (3.30), p 
<0.001. There is no difference in the level of stigmatization regarding the presence of a person 
with depression in the family. Previous studies show that through contact with people with 
depression, the level of stigma decreases.  
Conclusions. The level of personal stigmatization towards people with depression is lower 
than compared to perceived stigmatization in Moldova. Further research is needed to 
understand the characteristics of stigma against depression. 
Key words: depression, stigmatization, mental health, addressing a specialist. 
 
168. THE TREATMENT OF RESISTANT SCHIZOPHRENIA 
Author: Cristina Putină  
Scientific adviser: Igor Nastas, MD, PhD, Associate professor, Department of Psychiatry, 
Narcology and Medical Psychology, Nicolae Testemitanu State University of Medicine and 
Pharmacy, Chisinau, Republic of Moldova  
 
The 8th International Medical Congress for Students and Young Doctors 
 ____________________________________________________________________________________ 
154 
 
Introduction. Schizophrenia is a severe mental disorder characterized by positive, negative 
and cognitive symptoms. Schizophrenia affects 1% of general population and one of its features 
is the heterogeneity of response to treatment. 20–30% of individuals with schizophrenia have 
treatment-resistant schizophrenia. Correctly identifying these patients could contribute to 
reduce burden in patients themselves, in society and in economy. In fact, TRS constitutes about 
60–70% of schizophrenia's cost burden. Three key elements define the concept of treatment 
resistant schizophrenia. These are: 1) a confirmed diagnosis of schizophrenia based on 
validated criteria; 2) adequate pharmacological treatment; and 3) persistence of significant 
symptoms despite this treatment.  
Aim of the study. Studying the particularities of the clinical evolution and the management 
methods of the resistant schizophrenia treatment. 
Materials and methods. The number of patients included in the study is 38 people who were 
previously diagnosed with schizophrenia. To these patients, the BPRS scale was performed to 
identify the response to the administered treatment.  Also in the study were taken into 
consideration the following criteria,such as: age, heredity, gender, number of recurrences and 
admissions, trigger factors, duration of psychotic episode, disease evolution over the years and 
what antipsychotics were administered. 
Results. In the study performed on 38 patients, using the BPRS scale, were identified only 3 
patients, who meet the criteria of resistant schizophrenia, the patients are male over 45 years 
old. Now, I am studying patient’s records to analyze other aspects and criteria that influence 
treatment resistance. By analyzing the treatment that follows, patients develop resistance to 
typical antipsychotics. A pattern of superiority for olanzapine, clozapine, and risperidone was 
seen in other efficacy outcomes, but results were not consistent and effect sizes were usually 
small. In addition, relatively few RCTs were available for antipsychotics other than clozapine, 
haloperidol, olanzapine, and risperidone. The most surprising finding was that clozapine was 
not significantly better than most other drugs. 
Conclusions. The clinical management of patients with treatment-resistant schizophrenia is 
still challenging despite years of extensive research. 2 antipsychotic drugs should be tried at 
adequate dosage and for an adequate period, and various factors that interfere with adherence 
should be ruled out before making a diagnosis of treatment-resistant schizophrenia. Clozapine 
should be used only when it is confirmed that patients have treatment-resistant schizophrenia 
and their condition fails to respond to atypical antipsychotics or typical antipsychotics. The 
same rule applies in identifying clozapine-resistant schizophrenia. Pharmacological 
augmentation strategies for managing clozapine-resistant schizophrenia are widely used in 
clinical practice. However, there is no strong evidence that supports augmentation as an 
effective treatment option. ECT may be an effective augmentation strategy in the treatment of 
clozapine-resistant schizophrenia. It should be emphasized that psychological and psychosocial 
care combined with medication treatment are the key factors in maximizing the effectiveness 
in the treatment of patients with treatment-resistant schizophrenia. 
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